RxDoctor Payments Data

Marisol Ocampo

Nurse Practitioner · Miami Beach, FLNPI 1457859720

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $28,787 of the $32,342 with a category attached, or 89.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,342in general payments, 2019–2025

Across 1,296 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Bristol Myers Squibb$2K
  • Sanofi$2K
  • Daiichi Sankyo Inc.$1K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$1,9206%
  • Speaking & faculty fees$5402%
  • Food & beverage$28,78789%
  • Education$1,0953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)173$3,489
AstraZeneca(2 entities)85$2,000
Pfizer70$1,866
Bristol Myers Squibb75$1,595
Sanofi28$1,548
Daiichi Sankyo Inc.36$1,265
Novartis65$1,162
Merck45$979
Incyte Corporation35$910
Eisai Inc.39$839
Beigene USA, Inc.30$767
E.r. Squibb & Sons, L.L.C.20$766
Astellas Pharma US Inc36$696
Karyopharm Therapeutics Inc.1$660
Genentech USA, Inc.35$659
Amgen38$637
Regeneron Healthcare Solutions, Inc.14$598
Array Biopharma Inc33$554
Janssen Scientific Affairs, LLC1$540
Bayer28$538
GSK20$528
AbbVie22$510
Seagen Inc.21$486
Epizyme, Inc.10$461
Springworks Therapeutics, Inc.13$427
Tempus AI, Inc9$391
Adaptive Biotechnologies Corporation14$389
Sirtex Medical Inc3$356
Exelixis Inc.18$352
EMD Serono, Inc.21$336
Sumitomo Pharma America, Inc.14$321
ADC Therapeutics America, Inc.11$296
Pharmacyclics LLC, An Abbvie Company12$288
Takeda Pharmaceuticals U.S.A., Inc.14$278
Beone Medicines USA, Inc.8$278
Deciphera Pharmaceuticals Inc.13$271
Gilead(2 entities)8$238
Myovant Sciences Inc.10$232
Jazz Pharmaceuticals Inc.8$232
Sobi, Inc6$230
Mirati Therapeutics, Inc.11$219
Taiho Oncology, Inc.9$214
Rigel Pharmaceuticals, Inc.2$208
Lilly USA, LLC9$170
Ipsen Biopharmaceuticals, Inc9$168
Myriad Genetic Laboratories, Inc.9$164
Morphosys, US Inc.8$157
AVEO Pharmaceuticals, Inc.6$152
Genmab U.S., Inc.6$132
Servier Pharmaceuticals LLC4$109
Immunogen, Inc.1$106
Boehringer Ingelheim4$102
Blueprint Medicines Corporation5$96
Stemline Therapeutics Inc.6$94
Tersera Therapeutics LLC3$90
Foundation Medicine, Inc.5$87
Sanofi US Services Inc.1$83
Dendreon Pharmaceuticals LLC3$73
Acceleron Pharma, Inc.4$72
Kyowa Kirin, Inc.4$72

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,342 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$13,870
Medicare patients
131
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate15$332,278
BrukinsaZanubrutinib15$166,507
EliquisApixaban20$17,728
Ondansetron Hcl26$604
Anastrozole33$459
Gabapentin12$248
Prednisone55$197
Pantoprazole Sodium12$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$839$332,27815 claims
Beigene USA, Inc.Brukinsa$767$166,50715 claims
PfizerEliquis$1,866$17,72820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →